milrinone has been researched along with aspirin in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (61.54) | 29.6817 |
2010's | 4 (30.77) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Bruzzese, D; Di Braccio, M; Fossa, P; Grossi, G; Leoncini, G; Mosti, L; Piras, D; Roma, G; Signorello, MG | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Alfei, S; Cichero, E; Damonte, G; Di Braccio, M; Fossa, P; Grossi, G; Leoncini, G; Signorello, MG | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Ikomi, F; Nakamura, K; Ohhashi, T | 1 |
Bolling, SF; Geltz, A; Spoor, MT | 1 |
Boyanova, D; Dandekar, T; Dittrich, M; Geiger, J; Hubertus, K; Mischnik, M; Philippi, N; Timmer, J; Wangorsch, G | 1 |
Adataya, S; Adatya, S; Eckman, P; John, R; Masri, C | 1 |
Blink, M; Brinkman, DMC; Buddingh', EP; Filippini, LHPM; Joosten, SA; Klein, RH | 1 |
1 review(s) available for milrinone and aspirin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for milrinone and aspirin
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosp
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Catalytic Domain; Coumarins; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; In Vitro Techniques; Models, Molecular; Morpholines; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones.
Topics: Benzimidazoles; Blood Platelets; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Platelet Aggregation Inhibitors; Pyrimidinones; Reference Values; Structure-Activity Relationship | 2013 |
Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterioles; Aspirin; Cerebrovascular Circulation; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclooxygenase Inhibitors; Drug Interactions; Endothelium, Vascular; Enzyme Inhibitors; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Male; Milrinone; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Phosphodiesterase Inhibitors; Pressure; Prostaglandins; Rabbits; Tetrazoles; Vasodilation; Vasodilator Agents | 2006 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality Therapy; Databases, Factual; Digoxin; Diuretics; Drug Therapy, Combination; Equipment Design; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Heart-Assist Devices; Humans; Male; Middle Aged; Milrinone; Mitral Valve; Mitral Valve Insufficiency; Norepinephrine; Pliability; Postoperative Complications; Prospective Studies; Recurrence; Reoperation; Spironolactone; Stroke Volume; Time Factors; Tricuspid Valve Insufficiency; Ultrasonography | 2006 |
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integrins; Milrinone; Models, Biological; Molecular Dynamics Simulation; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Ticlopidine | 2013 |
Loading conditions influence reliability of the echocardiographic ramp test in continuous-flow left ventricular assist devices.
Topics: Aged; Aspirin; Drug Therapy, Combination; Echocardiography; Eptifibatide; Heart-Assist Devices; Hemodynamics; Heparin; Humans; Male; Milrinone; Peptides; Reproducibility of Results; Thromboembolism; Ventricular Dysfunction, Left | 2013 |
[COVID-19-associated hyperinflammatory state in a 15-year-old female patient].
Topics: Adolescent; Anti-Inflammatory Agents; Aspirin; Cardiotonic Agents; COVID-19; COVID-19 Serological Testing; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Immunoglobulins, Intravenous; Methylprednisolone; Milrinone; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Treatment Outcome; Vasoconstrictor Agents | 2020 |